At ASCO: Bristol, Merck Drugs Shrink Several Tumor Types

New cancer drugs approved last year for Bristol-Myers Squibb (BMY) and Merck & Co. (MRK) are showing promise as treatment for a growing variety of tumor types, according to results from a quartet of studies released Friday at the American Society of Clinical Oncology’s (ASCO) annual meeting. Known as checkpoint inhibitors, or more specifically, PD-1 [...]